Dcgi

Dcgi News

COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group
India

COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group

The company has already conducted trials in the age group of 2-18 for two doses of Covaxin

Corbevax, Biological E's COVID-19 vaccine, gets DCGI's emergency use authorisation for children aged 5-12
India

Corbevax, Biological E's COVID-19 vaccine, gets DCGI's emergency use authorisation for children aged 5-12

The DCGI has also given restricted emergency use authorisation to Covaxin, manufactured by Hyderabad based pharmaceutical company - Bharat Biotech, for children between 6 and 12 years

DCGI clears Bharat Biotech's Covaxin for restricted emergency use in children aged 6-12 years
India

DCGI clears Bharat Biotech's Covaxin for restricted emergency use in children aged 6-12 years

Bharat Biotech has been asked to submit safety data alongwith the data on adverse event with due analysis, every 15 days for the first two months and after that monthly data for up to five months

DCGI grants emergency use permission to Sputnik Light COVID-19 vaccine
India

DCGI grants emergency use permission to Sputnik Light COVID-19 vaccine

Hyderabad-based Dr Reddy's Laboratories is the Indian partner of the Russian Direct Investment Fund (RDIF), which has sought approval from the Indian drug regulator for use of single-dose Russia's Sputnik Light one shot

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know
Health

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know

Molnupiravir, developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US pharma giant Merck, was approved for emergency use in India on Tuesday

Houston COVID-19 vaccine Corbevax gets DCGI approval for use in India
India

Houston COVID-19 vaccine Corbevax gets DCGI approval for use in India

The vaccine uses an older recombinant protein yeast fermentation technology similar to that used for the recombinant hepatitis B vaccine which has been around for 40 years.

Hydroxyurea gets DCGI nod for treatment of sickle cell anaemia: all you need to know
Health

Hydroxyurea gets DCGI nod for treatment of sickle cell anaemia: all you need to know

Sickle cell anemia is one of a group of disorders known as sickle cell disease. Sickle cell anemia is an inherited red blood cell disorder in which there aren't enough healthy red blood cells to carry oxygen throughout your body.

When is the ideal time for children to get the COVID-19 vaccine? Experts give their opinion
India

When is the ideal time for children to get the COVID-19 vaccine? Experts give their opinion

Arora said, "Very soon, mRNA vaccine is also coming. Based on international data, it is very encouraging that we can use that for children."

Biological E seeks DCGI approval to conduct Phase 3 trials for Corbevax as booster dose for Covishield, Covaxin
India

Biological E seeks DCGI approval to conduct Phase 3 trials for Corbevax as booster dose for Covishield, Covaxin

Currently, phase 2/3 trials of the RBD protein sub-unit vaccine is underway and the results are likely to be declared this month.

SEC recommends DCGI to approve Bharat Biotech's Covaxin for children between 2-18 years of age
India

SEC recommends DCGI to approve Bharat Biotech's Covaxin for children between 2-18 years of age

If approved, the two-dose vaccine will be given to children within 20 days apart.

Bharat Biotech submits vaccine data for phase 2/3 trials on children between 2-18 years to DCGI
India

Bharat Biotech submits vaccine data for phase 2/3 trials on children between 2-18 years to DCGI

The paediatric Covaxin is similar to the one administered to adults - two doses of the vaccine given 28 days apart.

Indian drug regulator allows Cadila Healthcare to conduct phase III trials for two-dose COVID-19 vaccine
India

Indian drug regulator allows Cadila Healthcare to conduct phase III trials for two-dose COVID-19 vaccine

The company has already received the emergency use authorization from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses

ZyCoV-D to come at
India

ZyCoV-D to come at "affordable price", market launch likely by Sept end, says Zydus group MD

ZyCoV-D was approved by the country’s apex drug regulator, Drug Controller General of India (DCGI), on August 20. The first indigenously-developed vaccine in India is Bharat Biotech’s Covaxin.

Zydus Cadila applies for emergency use authorisation for COVID-19 vaccine ZyCoV-D with DCGI
India

Zydus Cadila applies for emergency use authorisation for COVID-19 vaccine ZyCoV-D with DCGI

ZyCoV-D, a Plasmid DNA vaccine against COVID-19, will help not only adults but also adolescents in the 12 to 18 years age group, Zydus Cadila said

Moderna's COVID-19 vaccine gets approval for restricted emergency use, confirms Centre
India

Moderna's COVID-19 vaccine gets approval for restricted emergency use, confirms Centre

Earlier news agency PTI had reported that the DCGI has granted permission to Cipla to import Moderna's COVID-19 vaccine for restricted emergency use in the country.

Explained: Why WHO's emergency usage listing is important for Bharat Biotech's COVAXIN
India

Explained: Why WHO's emergency usage listing is important for Bharat Biotech's COVAXIN

The European Union (EU), United Kingdom (UK) and Canada have not included COVAXIN in their approved list of vaccines as it has not been approved by the WHO

Serum Institute gets DCGI approval to manufacture Russia's Sputnik V COVID-19 vaccine
India

Serum Institute gets DCGI approval to manufacture Russia's Sputnik V COVID-19 vaccine

The SII plans to seek restricted emergency use permission of the vaccine in India.

Serum Institute of India gets DCGI's nod to manufacture Sputnik V in India for test, analysis
India

Serum Institute of India gets DCGI's nod to manufacture Sputnik V in India for test, analysis

The Pune-based firm has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology in Moscow for developing Sputnik V at its licensed Hadapsar facility

DCGI eases norms for clearing foreign-made COVID-19 vaccines to bolster availability of shots
India

DCGI eases norms for clearing foreign-made COVID-19 vaccines to bolster availability of shots

These exemptions have been made in light of the huge vaccination requirements in India in the wake of the recent surge of COVID-19 cases and the need for increased availability of imported vaccines to meet national requirements